Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2015

01-12-2015 | Translational Research and Biomarkers

Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy

Authors: Kazuhiro Ezaka, MD, Mitsuro Kanda, MD, PhD, Hiroyuki Sugimoto, MD, PhD, Dai Shimizu, MD, Hisaharu Oya, MD, PhD, Shuji Nomoto, MD, PhD, Satoshi Sueoka, MD, Yuri Tanaka, MD, Hideki Takami, MD, PhD, Ryoji Hashimoto, MD, Yukiyasu Okamura, MD, PhD, Suguru Yamada, MD, PhD, Tsutomu Fujii, MD, PhD, Goro Nakayama, MD, PhD, Masahiko Koike, MD, PhD, Michitaka Fujiwara, MD, PhD, Yasuhiro Kodera, MD, PhD

Published in: Annals of Surgical Oncology | Special Issue 3/2015

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) frequently recurs after curative resection. Therefore, the availability of sensitive biomarkers for progression and recurrence is essential for managing patients’ clinical course. Adherens junctions associated protein 1 (AJAP1) may serve this purpose, because it mediates activities of tumor cells.

Methods

AJAP1 mRNA levels and those of genes encoding potential interacting proteins, such as SRC in HCC cell lines, and 144 pairs of resected liver tissues were determined as well as the methylation status of the AJAP1 promoter and copy number changes at AJAP1 locus. The expression pattern of AJAP1 protein was evaluated using immunohistochemistry.

Results

AJAP1 mRNA levels varied among nine HCC cell lines, and AJAP1 expression was reactivated after demethylation of its promoter. AJAP1 mRNA levels correlated inversely with those of SRC in HCC cell lines and tissues. AJAP1 mRNA levels were suppressed in HCC tissues. The expression pattern of AJAP1 correlated significantly with that of AJAP1 mRNA. Low levels of AJAP1 mRNA in patients with HCC associated significantly with elevated levels of tumor markers, larger tumor size, serosal infiltration, vascular invasion, hypermethylation of the AJAP1 promoter, and copy number loss at AJAP1 locus. Patients with low levels of AJAP1 expression were more likely to experience shorter disease-free survival (DFS), and multivariate analysis identified low AJAP1 expression as an independent factor for predicting DFS.

Conclusions

AJAP1 may function as a key regulatory molecule associated with the recurrence of HCC. Hypermethylation of the AJAP1 promoter is a key regulatory mechanism controlling AJAP1 expression.
Appendix
Available only for authorised users
Literature
1.
Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol. 2013;19:7316–26.PubMedPubMedCentralCrossRef
2.
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.PubMedCrossRef
3.
4.
5.
Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. Liver Int. 2011;31:146–62.PubMedCrossRef
6.
Oya H, Kanda M, Sugimoto H, et al. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol. 2014;50:590–600.PubMedCrossRef
7.
Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144:512–27.PubMedPubMedCentralCrossRef
8.
9.
Bharti S, Handrow-Metzmacher H, Zickenheiner S, Zeitvogel A, Baumann R, Starzinski-Powitz A. Novel membrane protein shrew-1 targets to cadherin-mediated junctions in polarized epithelial cells. Mol Biol Cell. 2004;15:397–406.PubMedPubMedCentralCrossRef
10.
11.
Zeng L, Fee BE, Rivas MV, Lin J, Adamson DC. Adherens junctional associated protein-1: a novel 1p36 tumor suppressor candidate in gliomas (review). Int J Oncol. 2014;45:13–7.PubMed
12.
Sun M, Eshleman JR, Ferrell LD, et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology. 2001;33:1415–24.PubMedCrossRef
13.
Mori T, Nomoto S, Koshikawa K, et al. Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma. Liver Int. 2005;25:380–8.PubMedCrossRef
14.
Zhang H, Zhai Y, Hu Z, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet. 2010;42:755–8.PubMedCrossRef
15.
McDonald JM, Dunlap S, Cogdell D, et al. The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration. Cancer Biol Ther. 2006;5:300–4.PubMedCrossRef
16.
Cogdell D, Chung W, Liu Y, et al. Tumor-associated methylation of the putative tumor suppressor AJAP1 gene and association between decreased AJAP1 expression and shorter survival in patients with glioma. Chin J Cancer. 2011;30:247–53.PubMedPubMedCentralCrossRef
17.
Kanda M, Nomoto S, Oya H, et al. Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. Int J Oncol. 2014;44:44–52.PubMed
18.
Sobin LH, Gospodarowicz MK, Wittekind C. International union against cancer, TNM classification of malignant tumors. 7th ed. New York: Wiley-Blackwell; 2009.
19.
Kanda M, Sugimoto H, Nomoto S, et al. Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinoma. Int J Oncol. 2014;45:2005–12.PubMed
20.
Kanda M, Sugimoto H, Nomoto S, et al. B-cell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma. Int J Oncol. 2015;46:641–8.PubMed
21.
22.
Kanda M, Shimizu D, Nomoto S, et al. Clinical significance of expression and epigenetic profiling of TUSC1 in gastric cancer. J Surg Oncol. 2014;110:136–44.PubMedCrossRef
23.
Takai D, Jones PA. The CpG island searcher: a new WWW resource. In Silico Biol. 2003;3:235–40.PubMed
24.
Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13:484–92.PubMedCrossRef
25.
Hibino S, Kanda M, Oya H, et al. Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus. Oncol Rep. 2014;31:693–700.PubMed
26.
Shimizu D, Kanda M, Nomoto S, et al. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma. Oncol Rep. 2014;31:1305–13.PubMed
27.
Kang YK, Hong SW, Lee H, Kim WH. Prognostic implications of ezrin expression in human hepatocellular carcinoma. Mol Carcinog. 2010;49:798–804.PubMed
28.
Lau GM, Lau GM, Yu GL, et al. Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Dig Dis Sci. 2009;54:1465–74.PubMedCrossRef
29.
30.
Kawahara T, Hotta N, Ozawa Y, et al. Quantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinoma-associated molecule that regulates cell adhesion and migration by stabilization of focal adhesion complex. PLoS One. 2013;8:e79654.PubMedPubMedCentralCrossRef
31.
Yam JW, Tse EY, Ng IO. Role and significance of focal adhesion proteins in hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:520–30.PubMedCrossRef
32.
Tanaka Y, Kanda M, Sugimoto H, et al. Translational implication of Kallmann syndrome-1 gene expression in hepatocellular carcinoma. Int J Oncol. 2015;46:2546–54.PubMed
33.
Takami H, Kanda M, Oya H, et al. Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients. J Surg Oncol. 2013;108:557–62.PubMedCrossRef
34.
Kanda M, Oya H, Nomoto S, et al. Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer. Dig Dis Sci. 2014;60:1256–64.PubMedCrossRef
35.
Han L, Zhang KL, Zhang JX, et al. AJAP1 is dysregulated at an early stage of gliomagenesis and suppresses invasion through cytoskeleton reorganization. CNS Neurosci Ther. 2014;20:429–37.PubMedPubMedCentralCrossRef
36.
Schreiner A, Ruonala M, Jakob V, et al. Junction protein shrew-1 influences cell invasion and interacts with invasion-promoting protein CD147. Mol Biol Cell. 2007;18:1272–81.PubMedPubMedCentralCrossRef
37.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.PubMedCrossRef
38.
Herath NI, Leggett BA, MacDonald GA. Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol. 2006;21:15–21.PubMedCrossRef
39.
Herceg Z, Paliwal A. Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat Res. 2011;727:55–61.PubMedCrossRef
40.
Fang W, Piao Z, Simon D, Sheu JC, Huang S. Mapping of a minimal deleted region in human hepatocellular carcinoma to 1p36.13-p36.23 and mutational analysis of the RIZ (PRDM2) gene localized to the region. Genes Chromosomes Cancer. 2000;28:269–75.PubMedCrossRef
41.
Zeng L, Kang C, Di C, et al. The adherens junction-associated protein 1 is a negative transcriptional regulator of MAGEA2, which potentiates temozolomide-induced apoptosis in GBM. Int J Oncol. 2014;44:1243–51.PubMed
42.
Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer. 2008;8:835–50.PubMedCrossRef
43.
Carpenter G, Red Brewer M. EpCAM: another surface-to-nucleus missile. Cancer Cell. 2009;15:165–6.PubMedCrossRef
44.
45.
Frame MC. Newest findings on the oldest oncogene; how activated src does it. J Cell Sci. 2004;117:989–98.PubMedCrossRef
46.
Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol. 2004;167:223–9.PubMedPubMedCentralCrossRef
47.
Sanchez-Tillo E, Lazaro A, Torrent R, et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene. 2010;29:3490–500.PubMedCrossRef
48.
49.
50.
Ning Z, Wang A, Liang J, et al. USP22 promotes epithelial-mesenchymal transition via the FAK pathway in pancreatic cancer cells. Oncol Rep. 2014;32:1451–8.PubMed
Metadata
Title
Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy
Authors
Kazuhiro Ezaka, MD
Mitsuro Kanda, MD, PhD
Hiroyuki Sugimoto, MD, PhD
Dai Shimizu, MD
Hisaharu Oya, MD, PhD
Shuji Nomoto, MD, PhD
Satoshi Sueoka, MD
Yuri Tanaka, MD
Hideki Takami, MD, PhD
Ryoji Hashimoto, MD
Yukiyasu Okamura, MD, PhD
Suguru Yamada, MD, PhD
Tsutomu Fujii, MD, PhD
Goro Nakayama, MD, PhD
Masahiko Koike, MD, PhD
Michitaka Fujiwara, MD, PhD
Yasuhiro Kodera, MD, PhD
Publication date
01-12-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4695-9

Other articles of this Special Issue 3/2015

Annals of Surgical Oncology 3/2015 Go to the issue

Breast Oncology

Reoperation for Complications after Lumpectomy and Mastectomy for Breast Cancer from the 2012 National Surgical Quality Improvement Program (ACS-NSQIP)

Erratum

Erratum to: Pure Laparoscopic Liver Resection for Large Malignant Tumors: Does Size Matter?

Thoracic Oncology

Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy

Translational Research and Biomarkers

A Cancer Reprogramming Method Using MicroRNAs as a Novel Therapeutic Approach against Colon Cancer

Palliative Care

Palliative Care Training in Surgical Oncology and Hepatobiliary Fellowships: A National Survey of Program Directors

Erratum

Erratum to: Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer